USTR 301 report spells out big pharma’s Asian patent concerns
The office of the United States Trade Representative has just released its annual 301 Special Report, a review of the state of intellectual property rights and their enforcement around the world. Although comprehensive in scope, the report makes…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.